文献速递自身免疫性与大疱性皮肤病

TWEAK/Fn14激活参与大疱性类天疱疮的发病机制

TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid.
PubMed 文献 · J Invest Dermatol · 2017-03-27

研究探讨TWEAK/Fn14在大疱性类天疱疮(BP)中的作用,发现患者血清TWEAK升高且与抗BP180抗体正相关,皮损中TWEAK和Fn14强表达且与BP180表达呈相反关系。体外TWEAK刺激降低HaCaT细胞BP180表达并抑制细胞黏附,Fn14敲低可保护BP180和黏附,该效应涉及ERK、NF-κB通路及ADAM17。

要点

  • BP患者血清TWEAK升高且与抗BP180抗体正相关。
  • TWEAK经Fn14、ERK/NF-κB及ADAM17降低BP180和细胞黏附。
  • TWEAK可能作为BP的生物标志物或治疗靶点。

核心结论

  • TWEAK可能通过降低BP180表达和细胞黏附参与BP发病,涉及ERK和NF-κB通路激活。
  • TWEAK可能作为BP的生物标志物或治疗靶点。

研究设计与样本

  • 研究检测BP患者血清TWEAK水平及与抗BP180抗体的相关性。
  • 对BP患者皮肤样本进行免疫组化检测TWEAK和Fn14表达。
  • 体外用TWEAK刺激HaCaT细胞,并用Fn14或ADAM17小干扰RNA干预。

主要发现

  • BP患者血清TWEAK水平升高,且与抗BP180抗体呈正相关。
  • BP患者皮肤样本中TWEAK和Fn14强表达,TWEAK与BP180表达呈相反关系。
  • 体外TWEAK刺激降低HaCaT细胞BP180表达并抑制细胞与培养皿的黏附。
  • 转染Fn14小干扰RNA可保留BP180并保护细胞免于失去黏附。
  • TWEAK效应与ERK和NF-κB通路及下游ADAMs激活相关,ADAM17参与TWEAK诱导的BP180丢失。

临床怎么用

  • TWEAK/Fn14通路可能为BP提供新的生物标志物或治疗靶点方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TWEAK participates in various cellular effects by engaging its receptor of Fn14. Increased levels of soluble TWEAK are associated with systemic autoimmunity in patients with lupus erythematosus, rheumatoid arthritis, or dermatomyositis. However, the role of TWEAK in bullous pemphigoid (BP) remains unknown. In this study, we found an elevated serum level of TWEAK and a positive correlation between serum TWEAK and anti-BP180 antibodies. Immunohistochemistry showed strong TWEAK and Fn14 expression and implied an opposite relationship between the TWEAK and BP180 expression in skin samples from BP patients. In vitro TWEAK stimuli reduced BP180 expression in HaCaT cells and inhibited the adhesion of cells to the culture dish. Consistently, the transfection of Fn14 small interfering RNA preserved BP180 and protected cells from losing adherence. Moreover, such effect of TWEAK correlated with activation of the extracellular signal-regulated kinase and NF-κB pathways and downstream ADAMs. By silencing ADAM17 with small interfering RNA, we showed that ADAM17 participated in TWEAK-induced BP180 loss. Therefore, TWEAK may contribute to the pathogenesis of BP by reducing BP180 expression and cellular adherence, involving the activation of ERK and NF-κB pathways. TWEAK may serve as a biomarker or therapeutic target of BP.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Peng L, Li L, et al. TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid. J Invest Dermatol. 2017. PMID: 28351660. doi:10.1016/j.jid.2017.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。